How much funding has Kelonia raised?

Kelonia has raised $50.0M in total funding, most recently a Series A round.

Where is Kelonia headquartered?

Kelonia is headquartered in Boston, Massachusetts, United States.

What industry is Kelonia in?

Kelonia operates in Biotech, Healthcare.

Kelonia

Delivering on the Promise of Genetic Medicine

Boston, United States · Founded 2021 · $50.0M raised

Biotech

Healthcare

Headquarters: Boston, Massachusetts
Employees: 11–50
Founded: 2021
Business Model: B2B

Website: keloniatx.com
Total Funding: $50.0M
Last Round: $50.0M Series AApr 2022
Rounds: 1

About

Kelonia Therapeutics is a clinical-stage gene therapy company headquartered in Boston, Massachusetts, focused on in vivo gene delivery to advance a new era of genetic medicines. Founded in 2021, Kelonia is developing proprietary delivery platforms designed to address a broad range of genetic diseases with greater accessibility and scalability than ex vivo approaches. The company's pipeline targets diseases amenable to gene correction, with preclinical and early clinical programs spanning oncology and rare genetic conditions. Kelonia is led by founder and CEO Kevin Friedman, PhD, and backed by investors including Alta Partners and Venrock. The company has assembled a multidisciplinary team of scientists, clinicians, and industry veterans from leading pharma and biotech organizations.

Summary

Kelonia is a Biotech company based in Boston, United States, founded in 2021. It has raised $50.0M in total across 1 round, most recently a $50.0M Series A round in Apr 2022.

LinkedIn X (Twitter)